OUR COMMITMENT FOR PATIENTS

Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth

The project is part of the Group’s industrial plan to support its global growth The site will specialize in the production of sterile biological products, DPI and carbon minimal inhalers for the treatment of respiratory diseases, with a primary focus on the latter The redevelopment of the facility and its surrounding area will be centered on innovation and sustainability criteria   Milan, March 27th, 2025 – Chiesi Group, a global biopharmaceutical company headquartered in Parma, Italy, has announced a major investment in Nerviano (Milan, Italy), with the construction of a new facility for the production of its therapeutic solutions. The project entails the revitalization of this historical production site, first established in 1965 as an oncology research centre for Farmitalia Carlo Erba and subsequently subjected to several ownership changes, until its closure in 2024. The facility will be primarily dedicated to manufacturing carbon minimal inhalers, reinforcing the company’s commitment to both patients’ health and sustainable healthcare solutions. Dry powder inhalers and sterile biological products will also be developed in Nerviano. The €430 million investment, spread between 2025 and 2030, will fund the redevelopment of a 124,000-square-meter industrial area, transforming it into an international center of excellence. This initiative is part of the Group’s global industrial strategy, which includes ongoing investments in its facilities in Parma (Italy) and Blois (France) and operations in Santana de Parnaíba (Brazil) to meet the growing needs of people living with respiratory conditions. The objective is to support the company’s growth and its goal of achieving Net Zero emissions by 2035.   The redevelopment will modernize the existing site, originally built in the 1980s, turning it into a next-generation production center. Once fully operational, the site will feature over 3,000 square meters of laboratory space and a photovoltaic park with an installed capacity sufficient to ensure the plant's energy self-sufficiency. Adjacent to the industrial facility, a 20,000-square-meter wooded area will undergo a regeneration project.   Beyond its environmental and technological advancements, the investment will deliver tangible benefits to the local community. The site is expected to create approximately 300 new jobs by 2029, stimulating economic growth in the region.   "We chose Nerviano for its strategic location and the potential of the industrial area, which we will transform into a center of excellence for the production of next-generation inhalers," said Giuseppe Accogli, CEO of Chiesi Group. "This investment strengthens our presence in Italy and Europe, consolidates our leadership in the sector, and creates new growth opportunities for the local community. It also complements our significant investments in the Parma area, notably our recent Biotech Center launch."     About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.     Contacts for Media:   Gruppo Chiesi Laura Vergani, Senior Vice President, Global Communications & Public Affairs e-mail: mediarelations@chiesi.com   Davide Paterlini, Global External Communications Sr. Manager mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

LEED Certification: Sustainable Workspaces for People and the Planet

At Chiesi, we are committed to creating workspaces that prioritize both environmental sustainability and the well-being of those who inhabit them. The company aims to provide buildings that not only minimize their environmental impact but also foster healthy, productive environments for the people who work in them every day.    As a reflection of this dedication to sustainability and innovation, we have reached our important milestone of surpassing our strategic target of more than 80% LEED certified sites worldwide.    LEED (Leadership in Energy and Environmental Design) is an internationally recognized green building certification program that sets high standards for environmentally responsible buildings.    Each certification is achieved through rigorous third-party assessments, ensuring that Chiesi’s buildings reduce energy consumption, lower CO₂ emissions, and improve indoor environmental quality.    Since 2019, Chiesi has had 13 sites certified LEED, with ongoing efforts to create healthier, more efficient, and eco-friendly workspaces for both people and the planet.     Chiesi's headquarters in Parma has achieved LEED Platinum certification, the highest level of recognition in the LEED system, placing it among the top 35 buildings worldwide.   In addition to this remarkable achievement, our manufacturing facilities, which are the most energy-demanding part of our operations, have made significant progresses in enhancing energy efficiency and reducing emissions, and have been recognized with the LEED Certification.    Together we are building a more sustainable future, one building at a time.     Discover our LEED-certified buildings:        

In Memory of Dr. Paolo Chiesi: Visionary Leader and Innovator

Today marks the one-year anniversary of the passing of Dr. Paolo Chiesi, former Honorary President of Chiesi Group. Dr. Paolo Chiesi was a visionary leader and a cornerstone of Chiesi Group for almost sixty years. His contributions to scientific progress and innovation have left a lasting impact on the company and the global community.   Throughout his tenure, he provided invaluable guidance to the Research & Development department. His legacy includes over 50 patents and numerous scientific publications, reflecting his relentless pursuit of excellence.   Beyond his groundbreaking work, Dr. Paolo Chiesi was a source of inspiration to all who had the privilege of working with him. His profound scientific expertise, combined with his remarkable humanity, made him an extraordinary mentor and leader.   Dr. Paolo Chiesi's passion and dedication continue to inspire us every day. We remain forever grateful for his guidance and the significant impact he has had on our lives and our work.   About his career   Dr. Paolo Chiesi took his undergraduate degree in Chemistry at the University of Parma in 1964, and he graduated in Pharmacy at the same University in 1965. Shortly after, he began his professional career at Chiesi Group.  From 1985 to July 2023, Dr. Paolo served as Vice President of the Group. Leading the Research & Development department, he played a pivotal role in advancing therapies for respiratory, neonatal, and rare diseases.   In 2015, Dr. Paolo together with his brother Alberto, has been awarded by the Ernst & Young as the EY World Entrepreneur of the Year in the field of Healthcare and Life Science.   Dr. Paolo Chiesi was particularly active also in the field of international health cooperation. In 2005, he founded and chaired the Chiesi Foundation until 2021, championing initiatives to improve access to quality care for patients with chronic respiratory diseases in Latin America and for newborns and their mothers in Sub-Saharan Africa. In 2010, he received an honorary degree in Medicine from the University of Modena and Reggio Emilia, while in 2019 he has been appointed Honorary doctor at Karolinska Institutet for his long-standing commitment to vital treatment of the lungs of premature babies.

Embracing Sustainability and Inclusivity: Updated Code of Interdependence

As part of our ongoing commitment to sustainability, Chiesi has updated its Code of Interdependence, aligning it with the latest industry standards and best practices. By focusing on the Sustainable Development Goals (SDGs) where we and our partners can have the greatest impact, we actively contribute to the 2030 Sustainability Agenda.   Sustainability and inclusivity are at the heart of Chiesi’s approach to the pharmaceutical industry. Our Code of Interdependence, which serves as the Group’s Value Chain Code of Conduct, has recently been updated to better reflect our evolving goals and the latest industry standards.   The updated Code aligns with the 2023 Pharmaceutical Supply Chain Initiative (PSCI) principles, and incorporates the Science-Based Targets initiative (SBTi) as a foundation to promote best practices in emissions reductions and net-zero targets in line with climate science. Additionally, it reflects updates in internal policies, practices, procedures, and relevant regulations.   A key aspect of this revision was collaboration. During the September 2024 workshop, we engaged with our partners, gathering their insights and feedback. Combined with extensive benchmark analyses, these contributions have strengthened the framework, making it an even more effective tool for sustainable progress.   More than just a set of guidelines, the Code of Interdependence serves as a resource for Chiesi’s entire value chain—including suppliers, partners, and distributors—to advance toward more sustainable and inclusive business practices.   With this update, Chiesi is reinforcing its commitment to broadening the adoption of sustainable principles across its value chain, marking a significant step forward in our collective journey toward a more responsible and inclusive future.    Read the new Code of Interdependence  

Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth

Chiesi Group appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi to further enhance Board capabilities and internationalize leadership These senior business leaders bring diverse expertise and international experience, strengthening governance and international best practices, whilst supporting Chiesi's global ambitions New committees established: Governance, Nomination and Compensation; Audit and Risk; Strategy, Sustainability and Innovation   Parma, January 29th, 2025 – Chiesi, the international research-focused biopharmaceutical Group, announces the appointment of three new independent Non-Executive Directors (NEDs) to its Board: Roch Doliveux, Paolo Pucci and Daphne Quimi. Following a global search, the new Board members have joined the current five at Chiesi, effective January 28th, 2025.   The addition of three new NEDs is a significant part of Chiesi's broader strategy to enhance the Board’s capabilities, focusing on both upskilling and further internationalizing its leadership.   Driven by the continued foresight of the Chiesi family, this step represents a clear advancement in the company's efforts to enrich corporate governance as part of its ongoing international and patient impact growth. The new NEDs bring valuable expertise that will guide the company towards industry best practices.   By fostering diversity and introducing new competencies, they will support Chiesi’s commitment to sustainable growth, organizational transition, and international expansion, including into the important US market.   Furthermore, with the inclusion of these new members, Chiesi has also improved its Board functionality, particularly through the establishment of internal committees designed to enhance decision-making processes. The new committees are set up as follows: Governance, Nomination and Compensation Committee: Roch Doliveux (Chairperson), Maria Paola Chiesi, Daphne Quimi, Alessandro Chiesi Audit and Risk Committee: Daphne Quimi (Chairperson), Giacomo Chiesi, Paolo Pucci, Andrea Chiesi Strategy, Sustainability and Innovation Committee: Paolo Pucci (Chairperson), Maria Paola Chiesi, Roch Doliveux, Andrea Chiesi Each of the new Board members brings extensive experience to support Chiesi adapt to the rapidly evolving marketplace and continue its evolution:   Roch Doliveux has extensive leadership experience in Biopharmaceuticals and was CEO of UCB for ten years. He chairs the Boards of Pierre Fabre SA and Oxford Biomedica.   Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ArQule, leading it until its acquisition by Merck & Co. in 2020, and he held senior roles at Bayer Schering Pharma. He serves on the Boards of Replimune Group, Merus and West Pharmaceutical Services.   Daphne Quimi has made significant contributions to the pharmaceutical industry.  As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. She also held senior roles at Johnson & Johnson, Bristol-Myers Squibb and Avon. She serves on the Boards of Amylyx Pharmaceuticals and Century Therapeutics.   “We are thrilled to welcome Roch Doliveux, Paolo Pucci, and Daphne Quimi to our Board”, says Alessandro Chiesi, Chair. “Their experiences will enhance Chiesi’s governance and support our global ambitions. In line with our family’s vision, this move further reflects our commitment to constant improvement, and will allow us to even better focus on the strategic drivers of our company. It will benefit the Group as we continue to grow and internationalize, and we look forward to the positive impact they will bring.”   “I am confident Roch, Paolo, and Daphne will be excellent additions to the Chiesi Board,” says Giuseppe Accogli, CEO. “They all bring extensive international experience and diverse expertise, which will enhance our competitiveness. Their fresh perspectives and valuable skills will enrich our Board discussions, and strengthen our governance framework, which will help to unlock our potential to improve and develop as a company.”   About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.   For further information please visit www.chiesi.com   About the new Non-Executive Directors: Roch Doliveux has driven innovation and growth in healthcare through various leadership roles. He facilitated collaboration in medical research as Chairman of the Innovative Medicines Initiative and GLG Institute Healthcare. His previous NED roles included UCB and Stryker (USA). Currently, he chairs the Boards of Pierre Fabre Group and Oxford Biomedica, where he continues to contribute to advancing healthcare and mental health initiatives. Doliveux is a Swiss national.   Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ARQULE, leading it until its acquisition by Merck & Co. in 2020. At Bayer Schering Pharma, he held senior roles, including President of Global Oncology. His tenure at Eli Lilly included leadership positions in Sweden and Italy. Pucci also has extensive NED experience, serving on the Boards of companies like Merus NV, Tarus Therapeutics, and Replimune Group. Pucci is a dual US-Italian national.   Daphne Quimi has made significant contributions to the pharmaceutical industry. As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. With 13 years at Johnson & Johnson, she gained extensive experience in audit, FP&A, and reporting. She serves on the boards of Amylyx Pharmaceuticals and Century Therapeutics, playing key roles in IPOs, acquisitions and CEO transitions. Quimi is a US national.

Chiesi Group Reaffirms Its EcoVadis Platinum Medal

For the second consecutive year, Chiesi Group has been awarded the Platinum Medal by EcoVadis, ranking among the top 1% of companies worldwide for outstanding performance in Environment, Ethics, Labor and Human Rights, and Sustainable Procurement.   This achievement, which reflects a five-point improvement compared to our 2023 score, highlights Chiesi’s ongoing commitment to fostering a collaborative value chain ecosystem trough increasingly sustainable management systems and practices.   “Sustainability is a strategic driver for Chiesi,” says Cecilia Plicco, Head of Shared Value & Sustainability. “Our unwavering commitment drives us toward a more sustainable future for all, transforming the traditional concept of a supply chain into a value chain rooted in collaboration and respect for the planet and people.”   Guido D’Agostino, Head of Global Procurement, underscores the importance of partnership in achieving this goal: “We operate within an ecosystem. Engaging in dialogue and sharing values with our partners enables us to tackle major global challenges, such as respecting human rights and combating climate change, while also seizing business opportunities. Reaching our objectives depends on the contribution and collaboration of all our suppliers and strategic partners, who play a vital role in evolving Chiesi’s value chain.”   What is EcoVadis? EcoVadis is one of the world’s leading corporate sustainability rating platforms. The Platinum Medal is awarded annually to companies that excel in environmental, social, and ethical practices.   This recognition reinforces Chiesi Group’s dedication to a sustainable future, demonstrating that sustainability is at the core of our vision and actions.